REVIEW

Remembering your A, B, C’s: Alzheimer’s disease and ABCA1

Cutler T. Lewandowski, Megan S. Laham, Gregory R.J. Thatcher

Abstract  The function of ATP binding cassette protein A1 (ABCA1) is central to cholesterol mobilization. Reduced ABCA1 expression or activity is implicated in Alzheimer’s disease (AD) and other disorders. Therapeutic approaches to boost ABCA1 activity have yet to be translated successfully to the clinic. The risk factors for AD development and progression, including comorbid disorders such as type 2 diabetes and cardiovascular disease, highlight the intersection of cholesterol transport and inflammation. Upregulation of ABCA1 can positively impact APOE lipidation, insulin sensitivity, peripheral vascular and blood–brain barrier integrity, and anti-inflammatory signaling. Various strategies towards ABCA1-boosting compounds have been described, with a bias toward nuclear hormone receptor (NHR) agonists. These agonists display beneficial preclinical effects; however, important side effects have limited development. In particular, ligands that bind liver X receptor (LXR), the primary NHR that controls ABCA1 expression, have shown positive effects in AD mouse models; however, lipogenesis and unwanted increases in triglyceride production are often observed. The longstanding approach, focusing on LXRβ vs. LXRα selectivity, is over-simplistic and has failed. Novel approaches such as phenotypic screening may lead to small molecule NHR modulators that elevate ABCA1 function without inducing lipogenesis and are clinically translatable.

© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Alzheimer’s disease (AD) is the most prevalent form of dementia in the US and worldwide, and it is currently the sixth leading cause of death in the US. Age is the greatest risk factor for AD, which will translate to an increase in disease prevalence with increasing life expectancy globally: current estimates indicate the number of diagnosed cases in the US increasing from six million to fourteen million by 2050. The widespread prevalence of AD is contrasted by the dearth of available treatments. There are five FDA-approved small molecule drugs: donepezil, rivastigmine, and galantamine inhibit the acetylcholinesterase enzyme; memantine antagonizes the NMDA glutamate receptor; and a combination donepezil–memantine pill performs both functions. However, these treatments provide only temporary symptomatic improvement. They do not prevent, slow the progression, or alter the fatal prognosis of AD. The AD clinical trial failure rate (99.6% in the decade from 2002 to 2012) is the highest of any disease state, and there is an urgent need to discover and develop effective new therapies. The extremely high risk and cost of failure has led pharmaceutical companies to divest of AD drug development before Phase 2 proof-of-concept and pivotal Phase 3 clinical trials, which likely has led to premature abandonment of promising therapeutic strategies.

Diagnosis of AD rests on specialized tests for cognitive function combined with post-mortem histological analysis for hallmark AD pathology: a) extracellular amyloid plaques formed from amyloid-β (Aβ) peptide fragments and b) intracellular neurofibrillary tangles (NFT) composed of atypically phosphorylated tau protein. Inhibition of Aβ and tau peptide aggregation dominated early therapeutic approaches to AD, and the approval of aducanumab, in June 2021, is likely to revive these and other approaches targeting the removal of hallmark pathology. Although almost all disease-modifying AD therapeutics have failed in clinical trials, many targeted at Aβ have reported significant reductions in Aβ in these trials. This disconnect between attenuated Aβ without improved cognitive function has been explained by the need to treat patients in the prodromal stage of the disease. Longitudinal imaging studies have estimated that Aβ and NFT pathology develop up to three decades before symptoms, with brain atrophy (diminished hippocampal volume) and neuronal hypofunction (reduced glucose metabolism) preceding clinical onset by roughly ten years. Unfortunately, the move “to treat before clinical symptoms” is stymied by the lack of predictive diagnostics. In 2020, the Lancet Commission on “Dementia prevention, intervention, and care” concluded that imaging techniques for hallmark Aβ and tau pathology (and blood tests for Aβ) have not reached clinical significance for predicting cognitive decline. Indeed, it was concluded that most cognitively normal people with brain and/or plasma biomarkers for AD do not develop dementia within a clinically relevant timeframe.

Aducanumab, like other antibodies targeted at Aβ, dose-dependently reduced brain Aβ, as visualized by PET imaging. The FDA approval of aducanumab for prodromal AD, under the agency’s accelerated approval pathway, requires substantial evidence of effect on an intermediate biomarker (in this case Aβ) and reasonable likelihood of a meaningful clinical benefit, which the FDA hopes will be achieved in post-market clinical trials. The approval of aducanumab is highly controversial because of unproven efficacy and direct contradiction of the Lancet Commission’s findings on predictive biomarkers; however, it will likely maintain focus on clearance of Aβ as a clinical endpoint.

Many people develop a heavy Aβ burden but never suffer from cognitive decline. In addition, the brains of patients who suffer cognitive decline and are diagnosed with AD show a wide range of pathologies post-mortem, including Lewy bodies, microinfarcts, and TDP-43 aggregates; some do not show a heavy Aβ or NFT burden. The acronym ADRD (AD and related dementia) conveniently describes the disease from which the majority of those with dementia will die. Cognition declines with age, and ADRD may represent an accelerated version of normal aging phenomena driven by idiosyncratic loss of neural reserve. Extensive ongoing research aims to define lifestyle, clinical, and physiological factors that underlie the susceptibility or, conversely, the resilience to dementia during aging. Recent genome-wide association study (GWAS) reports highlighted pathways, such as lipid metabolism and immune signaling in the liver, distinct from traditional AD-associated genes and pathology that are associated with resilience to clinical dementia.

In contrast to the difficulty of assessing pathological progression toward AD prior to diagnosis, there are documented risk factors for clinical AD, which are readily measurable. These risk factors include innate genetic traits, such as APOE4 (apolipoprotein E ε4 genotype), unmodifiable risk factors, such as aging, and modifiable environmental or behavioral factors that can be quantified in a clinical setting (e.g., blood pressure). As detailed above, targeting a drug to an amyloid plaque has yet to produce a robust clinical cognitive benefit, whereas neutralizing a risk factor could provide a profound therapeutic impact on ADRD development and progression. This paradigm has been used successfully in cardiovascular disease (CVD) with low-density lipoprotein (LDL) lowering statins and anti-hypertensive medications reducing risk and improving disease-free survival.

The Lancet Commission report on risk factors for ADRD stated that reducing the dementia risk created from diseases such as type 2 diabetes (T2D) and obesity would have a significant impact on healthy aging with cognition intact. In recent years, appreciation has grown for the role of other pathophysiological factors, such as insulin resistance, neuroinflammation, and dyslipidemia, leading to ADRD progression; thus, new drug strategies should consider these facets of the disease. Chronic metabolic diseases, including T2D and CVD, represent a growing health burden driven by increasing obesity. T2D is a significant risk factor for comorbidity with ADRD, with dementia risk paralleling the duration and severity of T2D. Specifically, insulin resistance, impaired glucose metabolism, mitochondrial dysfunction, inflammation, dyslipidemia, and impaired cholesterol mobilization may be common underlying pathogenic promoters of dementia in T2D and ADRD. T2D is a major risk factor for CVD and recent findings demonstrate that risk factors contributing to CVD, including high LDL-cholesterol and blood pressure, also increase risk of developing AD. Insulin resistance contributes to AD pathogenesis even in patients without overt diabetes. In addition, the major genetic risk factor for ADRD, APOE4, shows significant association with T2D in several studies and contributes to increased LDL cholesterol levels that drive CVD progression.

In this review article, we will demonstrate that boosting ATP binding cassette A1 (ABCA1) levels fulfills many of the objectives introduced above (Fig. 1). Evidence suggests that increased ABCA1 activity is beneficial for CVD, T2D, and ADRD. Moreover, several mechanisms link ABCA1 function to Aβ clearance and to mechanisms associated with heightened risk associated with APOE4. Therapeutic approaches to increasing levels of
ABCA1 and Alzheimer’s disease drug discovery

Figure 1 Proposed beneficial roles of ABCA1 in AD, ADRD, and comorbidities. ABCA1 mediates cellular cholesterol efflux, such that increased ABCA1 expression would be expected to produce several direct and indirect beneficial effects via an enhancement of efflux activity. These effects would provide therapeutic efficacy both in the brain and in peripheral tissues.

ABCA1 in the brain will be discussed along with results from studies in preclinical models of AD.

2. ADRD and risk factors

2.1. Late onset AD versus rare familial AD (FAD)

ADRD is a disease of aging; incidence increases nearly twenty-fold from ages 65 to 90, and roughly one in every three over the age of 90 suffer from dementia. Mild cognitive impairment (MCI) can be seen as a normal consequence of aging; however, not all MCI transitions to ADRD. Oxidative damage to DNA, lipids, and proteins accumulates with aging against a background of weakened repair and clearance mechanisms, leading to attenuation of essential cellular functions, particularly in metabolism and mitochondrial function. With the exception of FAD, caused by inherited mutations in amyloid precursor protein (APP) or presenilin (PSEN) 1 or 2 genes that account for ≤1% of all cases, clinical diagnosis comes during the seventh decade of life or later.

Nevertheless, FAD transgenic (FAD-Tg) mice that overexpress these mutant forms of human APP, PSEN1, or PSEN2 alone or in combination, remain dominant in AD drug discovery, because FAD-Tg mice develop amyloid neuropathology similar to that seen in AD patients. FAD-Tg mice are generally studied as young adults (3–12 months of age) and do not reproduce NFT pathology, nor do the FAD-Tg mice that also express mutations in amyloid plaques and NFT pathologies contribute to profound pathologic effects of APOE4. Thus, APOE4 genotype profoundly affects AD pathogenesis in a dose and allele-dependent manner. Although the frequency of APOE4 allele is less than 14% in the global human population, the allele frequency in AD patients is 40%. Carriers of one APOE4 allele have a ~50% chance of developing AD, whereas in homozygotes the risk is >90%. Moreover, compared to non-carriers (mean age of onset = 84), APOE4 heterozygotes and homozygotes develop AD roughly 8 and 16 years earlier, respectively.

APOE4 is a “loss-of-function” isoform: restoration of function to that of APOE2 or APOE3 would ameliorate AD pathology in APOE4 carriers. This outcome holds true even if the alternative “gain of toxic function” hypothesis holds true. A proposed unique feature of the APOE4 isoform is increased intrinsic disorder, termed the “molten globule” state. Most proteins contain intrinsically disordered regions, and these proteins are often stabilized by protein—protein interactions with scaffold proteins and chaperones. In the absence of stabilization, these proteins, including APOE4, are more susceptible to proteolytic degradation. Consequently, there is less APOE4 than APOE3 available for apolipoprotein formation; APOE4-containing lipoproteins are poorly lipidated and are less stable.

The structural and functional APOE isoform-specific differences contribute to profound pathologic effects of APOE4. Thus, therapeutic approaches that correct APOE4-mediated pathologic...
mechanisms or render neutral the risk relative to APOE3 should be prioritized. This conclusion is amplified by a recent observation on one rare APOE variant with a significant impact on AD risk. As part of a study on an FAD population in Colombia, a woman was identified who developed MCI in her seventies, compared to a mean of 45 years old for her relatives; protection in this patient was derived from being homozygous for an ultra-rare APOE-Christchurch variant characterized by a single, R136S amino acid substitution. Reduced NFT pathology and neurodegeneration were observed, despite high Aβ levels characteristic of FAD being present. This case emphasizes the profound role of APOE in modulating neurodegeneration and progression to dementia in AD. Several studies have demonstrated an interplay of female sex with APOE4 in accentuating AD risk. In one meta-analysis, female APOE3/E4 heterozygotes exhibited odds ratios ranging from 2 to 4, compared to the odds ratio for male APOE3/E4 heterozygotes of <1.5. Subsequent studies have demonstrated significant, but more modest, effects of sex on APOE4-mediated AD risk.

2.3. Connectedness of APOE, T2D, CVD, and ADRD

Outside the CNS, two major chronic conditions—T2D and CVD—strongly drive risk of AD. T2D and CVD share close metabolic links, and their influence on AD is similarly driven by these metabolic factors. Epidemiological studies, systematic reviews, and meta-analyses have firmly established T2D as a risk factor for AD and related dementias, even after correction for underlying drivers such as obesity or physical inactivity. Changes to glucose homeostasis and insulin signaling significantly impact the brain. Excess insulin may compete with Aβ peptides for degradation by insulin-degrading enzyme. The connection between insulin resistance and AD pathogenesis is further bolstered by shared perturbations in cellular metabolism, inflammation secondary to deposition of advanced glycation end-products, and direct vascular damage. The links between CVD pathology and AD risk are similarly multifaceted. Elevations in cholesterol and blood pressure promote atherosclerosis in cerebral vessels, resulting in stiff, narrow vasculature that reduces cerebral perfusion and precipitates Aβ and NFT pathology formation. This hypoperfusion can be exacerbated, chronically, by heart arrhythmias, or, acutely and severely, by myocardial infarctions. Sudden brain ischemia causes immediate neuronal loss while also enhancing ongoing AD pathological processes.

Of particular interest is that T2D, CVD, TBI, and even behavioral risk factors, such as smoking status and exercise, drive AD risk in a synergistic fashion when combined with the APOE4 allele. APOE4 correlates with increased plasma LDL levels, which may partially explain its connection with T2D/CVD in AD risk. In some studies, relative risks increased from 1.5 to 2 for single risk factors up to 5–10 when APOE4 is present. The magnitude of this synergism highlights the importance of understanding the molecular basis of APOE4-mediated deficits and of the interactions among APOE4, other risk factors, and dementia.

There are two major pathophysiologic commonalities that tie together the biological traits of APOE4 and aging, comorbid conditions such as TBI, CVD, and T2D, and even lifestyle factors such as obesity and smoking: disrupted lipid homeostasis and chronically heightened inflammation. This conclusion is supported by GWAS evidence that has associated loci relating to cholesterol metabolism and immune function with AD and dementia. Drug candidates that impact the intersection of these two pathophysiological mediators would provide impactful, pleiotropic efficacy. This consideration has led us and others to suggest the ATP-binding cassette family member A1 (ABCA1) protein as a compelling therapeutic target for AD.

3. Roles of ABCA1 in health and disease

3.1. ABCA1 and its broad physiological roles

ABCA1 is expressed ubiquitously throughout the human body, with peripheral levels highest in liver hepatocytes. In the CNS, ABCA1 is found in neurons, astrocytes, and microglia. Human ABCA1, consisting of 2261 amino acids, is an integral membrane protein that utilizes ATP to transport cholesterol, phospholipids, and other lipid molecules to apolipoprotein carriers. In the plasma membrane and in intracellular organelles, including endosomes and lysosomes, ABCA1 associates with cholesterol-rich membrane domains, where it may serve to protect cells from excessive and potentially cytotoxic accumulation of free cholesterol. ABCA1 interacts with many of the protein components of HDL, namely APOA1, APOA2, APOA4, APOC1–3, and APOE, particularly when these apolipoproteins are minimally lipidated. ABCA1 is uniquely suited to add lipid to lipid-poor apolipoproteins, whereas other ABC family members (e.g., ABCG1/G4) and cholesterol transporters (e.g., SR-B1) interact with already-lipidated forms. In addition to this putative direct transfer function, ABCA1 has many indirect functions resulting from its influence on cellular cholesterol homeostasis. These effects, which are depicted in Fig. 1 and elaborated in greater detail in the following sections, help explain why ABCA1 represents such a promising target for therapeutics that might more broadly attenuate pathophysiologic processes shared between ADRD and its many underlying risk factors.

3.2. ABCA1 and CNS lipid transport

Cholesterol homeostasis is vital to CNS function. The brain contains 2% of the total mass of an adult human yet holds nearly 20% of the total cholesterol. Most brain cholesterol resides stably in specialized myelin membranes, but roughly 30% is found in cellular membranes of neurons and glial cells, where it actively moves or is metabolized within and between cells. Importantly, CNS and peripheral cholesterol pools are separated by the blood–brain barrier (BBB); thus, all CNS cholesterol is synthesized, transported, and recycled in situ. In adult brains, cholesterol synthesis and turnover occurs at a low, yet nonzero, rate. Although neurons and astrocytes both express cholesterol synthetic enzymes, neurons exhibit functional dependence on astrocytes for cholesterol delivery. CNS cholesterol transport occurs via formation of APOE-containing lipoproteins. Although APOE can be, and often is, synthesized by other cell types, astrocytes serve as the primary source of brain lipoproteins. Newly-synthesized APOE receives cholesterol and phospholipids via ABCA1, then is secreted into brain parenchyma as discoidal lipoproteins. Cells with “excess” cholesterol complete additional lipid transfer to promote maturation of this lipoprotein particle, which can ultimately be internalized by cells “deficient” in cholesterol, a process mediated by proteins such as LDL receptor or LDL receptor-related protein 1 (LRP1).
Neuronal cholesterol homeostasis is under tight control to allow adequate function and growth while preventing accumulation of cytotoxic free cholesterol. Internalization of lipoproteins via LRPI is a critical source of cholesterol for neurite outgrowth, synaptogenesis, and remodeling, but LRPI also exerts negative feedback to limit intracellular cholesterol concentrations. Lipoprotein receptors expressed at the BBB can promote cholesterol egress from the CNS. A second efflux mechanism occurs via CYP46A1, an enzyme that converts cholesterol to 24-hydroxycholesterol (24HC), which, unlike cholesterol itself, is BBB-permeable. 24HC is also an endogenous agonist of the liver X receptor (LXR) that drives transcription of key genes such as ABCA1, ABCG1, and APOE (Fig. 2).

3.3. Restoration of brain cholesterol homeostasis by boosting ABCA1

CNS cholesterol homeostasis is a critical and tightly regulated process dependent on APOE and strongly influenced by APOE isoform. As stated above, APOE4 represents a loss-of-function allele relative to the common, risk neutral APOE3 variant. Human plasma and cerebrospinal fluid exhibit isoform-dependent concentrations of APOE (APOE2 > E3 > E4). A similar isoform dependence occurs for APOE-promoted cholesterol efflux from CNS cells. In human iPSC-derived CNS models, APOE4 broadly disrupts cholesterol metabolism. Together, these deficits associated with APOE4 lead to smaller lipoproteins that contain less cholesterol. In fact, APOE3-containing lipoproteins carry up to three times as much cholesterol per gram of protein as their APOE4-containing counterparts.

Reduced lipidation of APOE4 produces broad functional consequences. Lipidation of APOE alters protein morphology to expose residues used for receptor binding and prevents toxic aggregation of unlipidated APOE. Poorly lipidated APOE4 is unstable and, hence, susceptible to proteolytic degradation leading to generation of neurotoxic fragments, and less efficient clearance of toxic Aβ species. Overloading membrane cholesterol in neurons reproduces AD phenotypes, including Aβ overproduction and disrupted axonal transport. In brain tissue from human AD patients, APOE4 is associated with heightened Aβ deposition, soluble oligomeric Aβ (sAβ) levels, and amyloid plaque pathology, in addition to elevated tau pathology.

Based on the evidence elaborated above, a primary hypothesis for therapeutically boosting ABCA1 is relatively straightforward: increasing cholesterol efflux to APOE, via induction of ABCA1, will restore lipidation of APOE4 and correct other AD-related phenotypes. Genetic knockout of Abca1 in mice dramatically reduces brain APOE lipidation and secretion and disturbs cholesterol homeostasis. Mouse ABCA1 overexpression enhances lipidation and reduces aggregation of APOE species. Treating mice with LXR agonist, elaborated in detail below, likewise raises APOE protein levels via ABCA1 action. Increased lipidated APOE, particularly improvement in APOE4 lipidation, plays a significant role in clearance and detoxification of Aβ species.

Moreover, ABCA1 induction may be beneficial for AD cholesterol homeostasis regardless of APOE4 status, as AD brain samples reveal plasma membrane cholesterol enrichment with disease progression. Endogenous control mechanisms that respond to excess cholesterol to promote ABCA1 expression are dysfunctional in AD patients; both circulating levels of 24HC and neuronal CYP46A1 expression are reduced. Consequently, cholesterol efflux capacity in AD patients is reduced by 30%, and less efficient lipidation of APOE4, independently of APOE genotype. Studies of genetic polymorphisms in ABCA1 have revealed increased or decreased risk of AD, possibly in a sex-dependent manner, associated with certain variants that alter cholesterol transport capacity. One specific loss-of-function mutation, ABCA1*N1800H, increased AD risk fourfold. Together, these data strongly support
the hypothesis that enhancement of ABCA1 expression and function could restore CNS cholesterol homeostasis and reverse AD phenotypes.

A new type of microglia, lipid droplet-accumulating microglia, resembling foamy macrophages in atherosclerotic lesions, has recently been shown to accumulate in the aging brain and to be associated with neurodegenerative disease. Intracellular lipid droplets, containing glycerolipids and cholesterol, are markers of inflammation. The compromised cholesterol trafficking of astrocytes underlies the detrimental effect of APOE4 on lipid metabolism and lipid trafficking between astrocytes and neurons. In astrocytes and neurons from APOE3 and APOE4 knock-in mice, APOE4-expressing astrocytes are also less able to metabolize fatty acids and to transport and to internalize fatty acids from neurons, a process mediated by APOE-lipid particles. The APOE4-induced defects in lipid transport and metabolism in neurons and glial cells leads to accumulation of lipid droplets, lipotoxicity, and decreased mitochondrial function; which can be reversed by ABCA1 activation. Similar observations on astrocyte-neuron dysfunction were made when neurons were subject to excitotoxicity induced by NMDA.

3.4. ABCA1 and peripheral lipid transport

Although APOE and cholesterol cannot cross the blood–brain barrier, peripheral lipid transport plays an important role in AD pathogenesis. It has been proposed that the protective role of ABCA1 in AD may derive from enhancing plasma HDL, APOA1, and APOE, equally as from direct CNS actions. Plasma lipoprotein metabolism is more varied than in the CNS, in which APOE dominates. Several lipoprotein particles contribute to vascular cholesterol deposition, inflammation, and atherogenesis to drive

![Figure 3](image-url)  

**Figure 3** APOE, ABCA1, and inflammation. (A) Neuronal NMDA stimulation increased fatty acid and triglycerides (TGs) leading to decreased mitochondrial respiration, lipid peroxidation, and increased reactive oxygen species (ROS); in turn leading to lipotoxicity and neuronal death. Transport of fatty acids, TGs and lipid peroxidation products (LPPs) from neurons to astrocytes by lipidated APOE rescued neurons by lysosomal catabolism of fatty acids, storage in lipid droplets, and use for mitochondrial oxidative phosphorylation; which was accompanied by transcriptional upregulation of LXR and NRF2 target genes. (B) APOE4 neurons showed 36% lower APOE, reduced neurite branching, elevated fatty acids and TGs, and decreased mitochondrial function and glucose metabolism. APOE4 astrocytes were less efficient at transporting lipids and fatty acids from neurons and at fatty acid catabolism and energy conversion, containing fragmented mitochondria and elevated TGs.
Atherosclerosis. Conversely, HDL particles are anti-atherogenic. HDL facilitates removal of cholesterol from vascular walls and peripheral tissues via reverse cholesterol transport (RCT), thereby preventing formation of cytotoxic oxidized lipid species and reducing inflammation and atherogenic lesion formation. ABCA1 contributes to formation of particles termed pre-βHDL, and ABCA1/ABCG1 promote formation of mature HDL particles. Reduced plasma cholesterol efflux capacity, which is directly tied to ABCA1 and ABCG1 expression, synergizes with other components of metabolic syndrome to promote atherogenesis. Pathological changes that occur during atherogenesis, such as oxidation of LDL, down-regulate ABCA1 expression. Tangier disease, characterized by ABCA1 loss-of-function mutations, leads to premature atherosclerosis, and ABCA1 variants that increase AD risk also have been associated with T2D and CVD risk. Increased peripheral atheroprotection via ABCA1 induction would promote cerebral vascular health, preserving BBB integrity and function, and, ultimately, protect against AD.

3.5. ABCA1 and insulin resistance

Insulin resistance plays a key role in the brain during AD pathogenesis. AD brains exhibit altered insulin-related gene expression and diminished phosphorylation of AKT and GSK3β, even in patients not diagnosed with T2D. Altered glucose homeostasis (i.e., cerebral hypometabolism) in neurons predicts cognitive decline in AD patients. Synaptic plasticity relies on insulin signaling, and insulin protects neurons from αβ-induced toxicity. Several large, long-term cohort studies demonstrated an association of use of metformin, an insulin sensitizing drug, with a significantly reduced risk of developing MCI or dementia in patients with diabetes. Two small, short-term pilot studies with metformin in non-diabetic patients with MCI or early AD showed improvements in cognitive performance, but long-term data are lacking. A larger Phase 2/3 trial is currently enrolling patients with MCI to study the effect of metformin on progression to AD (NCT04098666). Similarly, intranasal insulin improved cognition in pilot studies in early-stage AD patients. However, Phase 3 clinical trials with anti-diabetes agents rosiglitazone and pioglitazone demonstrated no efficacy in AD patients. Thus, the description of AD as “type 3 diabetes” is an oversimplification; however, therapeutic strategies that improve insulin sensitivity hold promise in AD. Boosting ABCA1 expression represents one such strategy. Tangier disease causes disrupted insulin homeostasis, and ABCA1 deletion in pancreatic β-cells and insulin target tissues reduces insulin release and sensitivity, respectively. Patients with pre-diabetes or T2D exhibit reduced adipose and liver ABCA1 expression and diminished cholesterol efflux capacity. These studies support pharmacological enhancement of ABCA1 as a therapeutic strategy to correct deficits in cholesterol transport and insulin resistance.

3.6. Inflammation: Role of ABCA1 and implications for ADRD

An increasing body of evidence suggests that a sustained, inappropriate inflammatory response is a driving mechanism behind AD pathology that underlies connections between peripheral risk factors and AD. The neural reserve or cognitive resilience in individuals that develop Aβ pathology without cognitive decline may be associated with resilience to neuroinflammation. Inflammation in the CNS and periphery is strongly associated with AD. A meta-analysis combining forty individual studies revealed higher plasma levels of cytokines (TNFα, IL1β, IL6, IL12, IL18, and TGFβ) in AD patients versus healthy controls. These cytokines may cross the BBB, inducing neuroinflammatory responses, or damage the BBB itself, further enhancing immune cell infiltration and reducing glucose transport into the brain. Microglia and astrocytes are the major mediators of immune response in the CNS. Microglial phagocytosis of toxic Aβ species is hypothesized to be beneficial during early AD pathogenesis. However, as disease progresses, microglial phagocytosis may be overwhelmed, without diminishing cytokine production, resulting in more immune cells being recruited to sites of inflammation, where they produce additional cytokines. Proinflammatory cytokines increase brain insulin resistance, damage synapses, and induce neuronal death. Neuroinflammation, particularly in response to Aβ pathology, is exacerbated in the presence of APOE4.

Murine genetic deletion of brain Abca1 enhances neuroinflammation and astrogliosis. In humans with ABCA1 mutations, plasma levels and immune cell expression of cytokines are elevated compared to healthy controls. This pro-inflammatory profile associated with diminished ABCA1 expression stems from excess free membrane cholesterol, which promotes mobilization of inflammatory mediators, such as toll-like receptors, to lipid rafts. Independent of cholesterol mobilization, interaction of ABCA1 with APOA1 activates JAK2/STAT3 to suppress proinflammatory cytokine production. Thus, pharmacologic enhancement of ABCA1 expression may attenuate pro-inflammatory states associated with AD pathogenesis.

4. Pharmacological approaches to boosting ABCA1 for ADRD therapy

4.1. Overview

The broad therapeutic efficacy expected from pharmacological enhancement of ABCA1 expression and function has led to numerous therapeutic strategies; however, no candidate has been successfully translated to clinical use. A brief overview will be presented, with a more detailed analysis of LXR agonists.

4.2. Apolipoprotein peptide mimetics

HDL peptide mimetics were developed that enhanced HDL levels and prevented atherogenic lesion formation. It was later determined that these peptides promoted ABCA1-mediated cholesterol efflux. The many apolipoprotein mimetics, can be grouped into two classes: APOA1 and APOE mimetics. The initial model for APOA1 mimetics was a peptide named 18A containing 18 amino-acids that forms an amphipathic helix. Newer analogs, Ac-MK-3200-235, mimic the structure of APOA1. Modifications of this peptide led to compounds with atheroprotective properties in mice. In AD models, D-4F enhanced APOE lipidation by ABCA1 and was anti-inflammatory and pro-cognitive. APOE-mimetic peptides include: COG1410, consisting of APOE residues 138–149; COG112, consisting of APOE residues 133–149; Ac-hE-18A-NH2, comprised of 18A linked to APOE residues 141–150; and CS-2563, consisting of the modified C-terminal APOE domain (aa238–266). Only CS-2563 directly
stimulates ABCA1-mediated cholesterol efflux. Despite anti-inflammatory and neuroprotective effects in models of neurodegeneration, these mimetics share poor CNS bioavailability. A smaller peptide of only five amino acids, termed CN-105, demonstrated improved brain bioavailability in humans and was reported to reduce Aβ pathology and cognitive deficits in APOE4-expressing FAD mice\(^{246,247}\). This peptide is in Phase 2A clinical trials for intracerebral hemorrhage (NCT03168581) and post-operative cognitive decline (NCT03802396).

### 4.3. Small molecule approaches to ABCA1 induction

Humans express 48 unique nuclear hormone receptors (NHRs) that share a common ancestral gene and, therefore, possess common structural motifs that include an N-terminal transactivation domain, a conserved DNA-binding domain, and a C-terminal ligand-binding domain\(^{248,249}\). While some of these receptors are well-characterized and have been exploited clinically (e.g., estrogen receptor α; ERs), a handful still possess the designation of “orphan receptor” because an endogenous ligand has yet to be identified\(^{250}\). ABCA1 expression is regulated primarily by LXR, retinoid X receptors (RXR), and peroxisome-proliferator activated receptors (PPAR). These represent the most well-studied therapeutic targets for ABCA1 induction by small molecules. Additional, non-NHR approaches are briefly summarized below:

1. **cAMP analogs, PKA activators, phosphodiesterase inhibitors, and adenosine A2A receptor agonists** are all designed to enhance the cAMP/PKA pathway, to increase ABCA1 expression and cholesterol efflux for anti-atherogenic and anti-inflammatory effects\(^{251,252}\).

2. **Anti-hypertensive agents and targets** have also been widely explored in AD: mechanisms include ABCA1-mediated cholesterol mobilization. Angiotensin II promotes intracellular cholesterol accumulation by reducing ABCA1 transcription via NHR downregulation, promoting foam cell formation and hampering glucose-stimulated insulin secretion from pancreatic β cells\(^{253,254}\), indicating beneficial roles for angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers. Calcium channel blockers are also used clinically for hypertension and CVD: two have been shown to increase ABCA1 expression: nifedipine, which activated PPARγ via an ERK1/2-dependent mechanism at a clinically relevant concentration\(^{255}\), and verapamil, which stimulated ABCA1 promoter activation independent from LXR, albeit at supratherapeutic concentrations of 10–30 μmol/L\(^{256}\).

3. **AMP-activated protein kinase (AMPK)** is a major metabolic regulator\(^{257}\), which provides antioxidant functions, plays a role in CVD, and is an indirect target of T2D drug metformin\(^{258}\). Two studies showed that AMPK agonists increased Abca1 and/or Abcg1 mRNA and cholesterol efflux to APOA1, although they disagreed on whether this effect was LXR-dependent or -independent\(^{259,260}\).

4. **Glucagon-like peptide-1 (GLP1)** is a short peptide hormone classically associated with simulating insulin release and attenuating glucagon release to lower plasma glucose\(^{261}\). GLP1 receptor agonists and inhibitors of the GLP1-degrading enzyme are used clinically in T2D. GLP1 is neuroprotective and GLP1 therapeutics were shown to upregulate cholesterol transporters, enhance cholesterol efflux, and reduced proinflammatory cytokine release in cell models\(^{262}\), although the mechanism is not fully defined\(^{263–265}\). Liraglutide, a GLP1 analog, is currently in a Phase 2 trial of patients with mild AD\(^{266}\).

5. The clinical use of the vitamin niacin (nicotinic acid) in hyperlipidemia and hypertriglyceridemia has been decreasing over the years: niacin increases HDL and reduces levels of LDL and VLDL\(^{267}\). Niacin influences a vast number of biological mechanisms, one of which is activation of the G-protein coupled receptor GPR109A\(^{268}\). Niacin increases ABCA1 expression via multiple pathways\(^{269–271}\).

6. **CYP46A1 catalyzes the conversion of cholesterol to 24HC, which permits BBB efflux and activates LXR endogenously\(^{272}\).** Increasing CYP46A1 activity to promote ABCA1 activity and restore CNS cholesterol homeostasis has been proposed in AD\(^{273}\). The HIV drug efavirenz induces CYP46A1 at a dose below that used in HIV patients and is in clinical trial for AD (NCT03706885). CYP46A1 expression is brain-specific, thereby minimizing peripheral side effects; however, direct activators of CYP46A1 may interact with other CYPs because of structural similarity\(^{274,275}\). Efavirenz analogs and CYP46A1 activators are in early development\(^{276}\).

7. **Histone deacetylase inhibitors (HDACi)** have been studied extensively in preclinical and early clinical trials in AD. HDACs are epigenetic erasers modulating histone-mediated chromatin control and transcriptional activation. HDACs have many non-histone protein substrates, which have often been found to mediate observed activity. Pan-HDACi trichostatin A upregulates ABCA1 and ABCG1 expression and stimulates cellular cholesterol efflux via induction of PPARγ\(^{277–279}\). Similarly, Class I HDACi were shown to promote astrocytic APOE secretion and upregulate ABCA1 expression\(^{280}\).

### 4.4. Nuclear hormone receptor signaling: RXR

RXRs function as heterodimeric binding partners not only with LXRs, but also with all other class II nuclear hormone receptors (NR1 subfamily), which include PPAR, retinoic acid receptors (RAR), constitutive androstane receptors, pregna X receptor, farnesoid X receptor (FXR), vitamin D receptor, and thyroid hormone receptors\(^{281}\). Most of these heterodimers function as permissive pairs, meaning that ligand activation of either RXR or its binding partner elicits similar effects\(^{282}\). Profiling of binding sites across the genome illustrated two key phenomena associated with this function: first, that most sites of LXR–DNA binding are shared with RXR but only a fraction of RXR binding sites are shared with LXR; and second, that these whole-genome binding profiles are quite different across cell types\(^{283}\). RXR agonists have many non-histone protein substrates, which have often been found to mediate observed activity. Pan-RXAc tri-chostatin A upregulates ABCA1 and ABCG1 expression and stimulates cellular cholesterol efflux via induction of PPARγ\(^{277–279}\). Similarly, Class I HDACi were shown to promote astrocytic APOE secretion and upregulate ABCA1 expression\(^{280}\).

RXRs have many non-histone protein substrates, which have often been found to mediate observed activity. Pan-RXAc tri-chostatin A upregulates ABCA1 and ABCG1 expression and stimulates cellular cholesterol efflux via induction of PPARγ\(^{277–279}\). Similarly, Class I HDACi were shown to promote astrocytic APOE secretion and upregulate ABCA1 expression\(^{280}\).
mice, without TG-related liver effects\textsuperscript{297,298}. Based on the many heterodimer interactions of RXR, biased agonism to induce ABCA1 in certain cells and tissues while avoiding hepatic lipogenesis appears feasible, possibly by selectively activating RXR–FXR or RXR–RAR heterodimers in preference to RXR–LXR\textsubscript{α} \textsuperscript{299–301}.

4.5. Nuclear hormone receptor signaling: PPAR

PPARs function \textit{via} heterodimer formation with RXR and are activated endogenously by oxidized fatty acids. The three PPAR isoforms perform overlapping yet distinct functions compared with each other and with LXR isoforms. PPARα is most prominent in fatty acid metabolism, PPARγ in glucose metabolism and anti-inflammation, and the less well-studied PPARβ/δ in fatty acid metabolism and anti-inflammation\textsuperscript{102}. All three isoforms have been shown to modulate ABCA1 expression levels\textsuperscript{303,304}, although this effect may require LXRα. PPARγ/RXR dimers have been proposed to control LXRα transcription by direct promoter binding\textsuperscript{305}. Various PPAR agonists have been used clinically in T2D and CVD. Gemfibrozil and other PPARα-selective agonists increase ABCA1 activity, improve HDL and TG levels in preclinical and clinical studies, and demonstrate efficacy in mouse AD models\textsuperscript{305–307}. Rosiglitazone and pioglitazone, used clinically in T2D, failed to show efficacy in AD clinical trials\textsuperscript{190}. Recently-developed PPARγ agonists continue to show positive effects on ABCA1 expression\textsuperscript{308,309}, and a PPARβ/δ agonist that increases ABCA1 has also been described\textsuperscript{310}. Various PPAR ligands have been described that interact with other NHRs\textsuperscript{311,312}. Furthermore, selective PPAR modulators (SPPARMs) have been explored\textsuperscript{113,314}.

4.6. Nuclear hormone receptor signaling: LXR

LXR is the primary NHR target for pharmacologic induction of ABCA1 expression. Humans express two isoforms: LXR\textsubscript{α} that is highly expressed in liver, small intestine, and adipose, and LXR\textsubscript{β} that demonstrates ubiquitous expression, including brain tissue\textsuperscript{106,315–317}. Endogenous oxysterols, e.g., 24HC, activate LXR, which acts \textit{via} LXR response elements consisting of two direct repeats of a consensus sequence (i.e., ATTGCA) occurring in the promoter regions of dozens of genes. LXR–DNA binding results in transactivation or transrepression of various target genes related to cholesterol transport (\textit{e.g.}, ABCA1) and synthesis, glucose metabolism, and inflammatory signaling\textsuperscript{318,319}. A final set of LXR target genes consists of the machinery that controls TG synthesis, both \textit{via} direct transcriptional activation and through upregulation of sterol-response element binding protein 1c (SREBP1c)\textsuperscript{320}. The earliest synthetic LXR agonist, T0901317 (T0), elicited potent responses in all of these transcriptional functions, demonstrating phenotypic improvements in mouse models, while also provoking TG overproduction and steatohepatitis\textsuperscript{321}.

Treatment of Lxr\textsubscript{α}–/– and Lxr\textsubscript{β}–/– mice with T0 demonstrated that hypertriglyceridemia was dependent on LXR\textsubscript{α} \textsuperscript{322}; thus, development of LXR\textsubscript{β}-selective agonists was prioritized. The first such “selective” agonist was GW3965; however, this compound ultimately was not phenotypically selective as it increased TGs in mouse models\textsuperscript{323–326}. Groups from Wyeth\textsuperscript{333}, Merck\textsuperscript{334}, Tokyo New Drug Research Laboratories\textsuperscript{335–336}, Vitae\textsuperscript{337,338}, and Bristol–Myers Squibb\textsuperscript{339–341} developed compounds highly selective for LXR\textsubscript{β} in receptor binding assays. BMS-852927 was originally described as an LXR\textsubscript{β}-selective partial agonist; and indeed, several LXR ligands show partial agonist activity at LXR\textsubscript{β}\textsuperscript{342–344}.

The results of development and characterization of LXR ligands in preclinical AD animal model studies are provided in Table 4. To summarize, early agonists T0 and GW3965 have been studied in multiple FAD models at doses ranging from 2.5 to 50 mg/kg/day and for treatment durations ranging from 6 days to 24 weeks, analyzed \textit{via} a host of behavioral, immunohistochemical, and biochemical techniques. Despite markedly varied treatment paradigms, these two compounds consistently increased ABCA1 and APOE expression, reduced Aβ and inflammatory marker levels, and improved cognitive performance. Inclusion of ABCA1 KO mice in some studies revealed that many of the observed therapeutic effects were dependent on ABCA1 expression. Newer, LXR\textsubscript{β}-selective ligands have primarily been tested in mouse models of atherosclerosis, but those evaluated for preclinical AD efficacy have demonstrated promising CNS pharmacokinetic–pharmacodynamic profiles and similar effects on AD-related pathology.

Two LXR\textsubscript{β} agonists, BMS-852927 and LXR-623, entered human clinical trials, with both compounds raising ABCA1 and ABCG1 expression levels\textsuperscript{342,343}; however, CNS adverse events were observed with LXR-623; and peripheral side effects, including neutropenia and increased TG and LDL levels, were observed with BMS-852927. The findings with BMS-852927 are consistent with the differences between rodent and human lipid physiology that will need to be addressed in future LXR-based drug development efforts. Specifically, rodents lack the plasma cholesterol ester transfer protein (CETP) that humans express, and LXR produces a distinct response on inducible degrader of LDL (IDOL) protein in rodents versus humans\textsuperscript{344,345}.

4.7. LXR-based drug discovery strategies for boosting ABCA1

Approaches to modulate LXR should be informed by the clinically successful modulation of other NHRs, notably ER. Selective estrogen receptor modulators (SERMs) are clinically important ER\textsubscript{α} ligands that deliver diverse pharmacology that is tissue-selective\textsuperscript{360–362}. Selective androgen receptor modulators have not reached the clinic, but are drugs of abuse in sports because of muscle and bone building effects, purportedly without side effects associated with steroids\textsuperscript{363}. SPPARMs have been introduced above. A similar concept has also been applied to label some LXR ligands as SLIMs (selective liver x receptor modulators)\textsuperscript{364,365}. For example, SR9238, described as a liver-selective LXR agonist, could be classed as a SLIM\textsuperscript{366,367}. The clinical relevance of NHR selective modulators rests on: a) enhancement of beneficial transcriptional events; without b) induction of transcriptional events associated with adverse effects. In this transcriptional context, the terms agonist and antagonist have little value. The transcriptional output of the NHR transcriptional complex depends on the cellular context (availability and binding of coregulators) and the ligand (differential stabilization of complexes)\textsuperscript{368}. For example, IMB-808 binds both LXR isoforms, but, in contrast to T0, cholesterol efflux genes are selectively induced over lipogenic genes because IMB-808 and T0 recruit different coregulators\textsuperscript{369}. LXR\textsubscript{β} binds to LXR response elements that occur in the promoter regions of dozens of genes leading to transactivation or transrepression of genes related to (A) cholesterol transport (\textit{e.g.}, ABCA1, APOE) and glucose metabolism; and (B) the cellular lipogenic machinery that controls triglyceride synthesis, both \textit{via} direct transcriptional activation and through upregulation of SREBP1c\textsuperscript{318,319}. Biochemical measurement of ligand binding to
| Compd. | Animal system | Key finding | Ref. |
|-------|---------------|-------------|------|
| Merck | Wistar Han Rats s.c. 4 days. Pharmacokinetics (PK) and peripheral lipids. | **Rats:** Plasma and liver TG not significantly increased by compound or GW3965. CL = 87 mL/min/kg; t1/2 = 2.9 h; F (%) = 71%; PPB = 98.2%. | Stachel et al., 2016 ^333 |
| Tg2576 FAD-Tg mice s.c. 3 weeks. PK, open field test (OFT), brain ABCA1, apoE, and Aβ. | **Mice:** PK comparable to rat. Increased ABCA1 and apoE. Decreased soluble Aβ. Reduced locomotion back to WT control. | |
| Rhesus monkey p.o. 2-weeks. PK, CSF apoE and Aβ, peripheral lipids. | **Rhesus monkey:** CL = 18 mL/min/kg; t1/2 = 2.0 h; F (%) = 77%; PPB = 99.3%. 3-fold increased apoE. CSF Aβ levels increased. No change in liver fat content. | |
| Vitae | C57BL/6 mice 3 mg/kg p.o. 4 h. PK and brain ABCA1. | **LXR** EC50 = 38 nmol/L; 77% Emax; LXRα EC50 = 166 nmol/L; 83% Emax | Tice et al., 2016 ^338 |
| Sprague–Dawley rats p.o. 4 h (5 mg/kg) or 5 days (1, 3, or 10 mg/kg qd). Brain ABCA1, CSF and cerebral Aβ40/Aβ42. | Mouse 4 h: Plasma 1075 nmol/L, brain = 1018 nmol/L; ABCA1 induction = 3.1× | |
| T9001317 APP23 FAD-Tg mice p.o. 6 days. Measured Aβ. | Increased ABCA1; Aβ40 and Aβ42 significantly decreased. | Koldamova et al., 2005 ^324 |
| APP23 mice p.o. 20–25 days. Cortical and hippocampal Aβ, ABCA1 and apoE, and inflammatory markers (mRNA). | Increased ABCA1 and apoE; significant reduction in insoluble Aβ with no effect on soluble Aβ. Inflammatory gene expression significantly decreased. | Lefterov et al., 2007 ^346 |
| Tg2576 mice p.o. 7 days. Contextual fear conditioning and contextual memory tasks (CFT). Hippocampal and cortical apoE and ABCA1 (mRNA), Aβ, and APP; plasma Aβ. | Complete reversal of cognitive deficits in CFT. Increased hippocampal ABCA1 and apoE. Significant Aβ42 reduction. No significant effects on full-length APP or processed APP. No significant effect on plasma Aβ. | Riddell et al., 2007 ^347 |
| APP23 mice p.o. 4 months with high-fat diet (HFD). Morris water maze (MWM) memory task. Cortical and hippocampal Aβ, apoE, ABCA1. | Reversal of MWM deficits caused by HFD. Reversal of increased insoluble Aβ due to HFD. Reduction of soluble Aβ beyond control diet levels. Increased ABCA1 and apoE. | Fitz et al., 2010 ^348 |
| APP23 mice p.o. 7 weeks. MWM. Drug levels, forebrain Aβ, ABCA1, and apoE. | No significant change in MWM performance. Brain drug level 5 nmol/g vs. blood 2 nmol/mL. Soluble and insoluble Aβ reduced. | Terwel et al., 2011 ^349 |
Table 1 (continued)

| Compd. | Animal system | Key finding | Ref. |
|--------|---------------|-------------|------|
| APPse/PS1 Δε9 (APP/PS1) mice p.o. 2 months. NOR and object location task. Brain and serum cholesterol profiles, hippocampal and cortical Aβ, ABCA1, and apoE. | ABCA1 and apoE increased. Improved cognitive performance. Increased cholesterol precursor levels. Increased ABCA1 and apoE. No change in Aβ plaque burden | Vanmierlo et al., 2011 |<sup>350</sup> |
| APP/PS1 mice p.o. 30 days. MWM. Hippocampal and cortical Aβ, GFAP, CD11b, ABCG1, apoE, and inflammatory markers. Nucleus basalis ChAT. | Improved MWM performance. Increased ABCG1 and apoJ, increased cholinergic neurons. Reduced astrocytosis and microgliosis, reduced COX2 and iNOS, reduced total Aβ. | Cui et al., 2012 |<sup>351</sup> |
| APP23 mice p.o. 50 days. Radial arm water maze (RWM) and CFT. Hippocampal and cortical Aβ, ABCA1, apoE; interstitial fluid Aβ and apoE. | Cognitive performance restored. No change in soluble or insoluble Aβ, but reduced Aβ in ISF. Increased ABCA1 and apoE; increased lipilation of ISF apoE. Increased ABCA1; increased apoE lipilation without change in total apoE. Significant reduction of soluble oAβ in APOE4 but not APOE3 mice, no change in Aβ plaques. CFT improvement in APOE4 but not APOE3 mice; no change in NOR. | Fitz et al., 2014 |<sup>352</sup> |
| Tg2576 mice p.o. 4 months (Aβ) or 6 days (CFT). | Improved contextual memory, reduced Aβ plaque and peptide. | Jiang et al., 2008 |<sup>148</sup> |
| APP/PS1 mice p.o. 8 or 24 weeks. NOR and Morris water maze (MWM). Cortical and hippocampal Aβ, ABCA1 and apoE. | Increased ABCA1 and apoE; increased CSF apoE lipilation. Reduced amyloid plaques and shifted Aβ from insoluble to soluble pool. Improved NOR and MWM performance. Enhanced odor habituation. Restored odor-evoked neural activity circuits. Reduced soluble and insoluble Aβ. Cortical apoE and apoA1, hippocampal apoA1, and CSF apoE and apoA1 increased. Hippocampal and CSF apoE unchanged. | Donkin et al., 2010 |<sup>445</sup> |
| Tg2576 mice p.o. 2 weeks. Odor habituation task, electrophysiology, whole-brain Aβ. | Improved MWM performance. Soluble/insoluble Aβ and p-tau unchanged. Increased ABCA1 and apoE. Astro- and microgliosis reduced to WT baseline. Increased neurogenesis. | Wesson et al., 2011 |<sup>354</sup> |
| APP/PS1 (±ABCA1 KO) p.o. 8 weeks. Cortical, hippocampal, and CSF apoE and apoA1. | Improved MWM performance. Soluble/insoluble Aβ and p-tau unchanged. Increased ABCA1 and apoE. Astro- and microgliosis reduced to WT baseline. Increased neurogenesis. | Stukas et al., 2012 |<sup>555</sup> |
| 3xTg FAD mice p.o. 12 weeks. MWM. Hippocampal and cortical Aβ, NFT, ABCA1, apoE; dentate gyrus nestin and pH3. | Improved MWM performance. Soluble/insoluble Aβ and p-tau unchanged. Increased ABCA1 and apoE. Astro- and microgliosis reduced to WT baseline. Increased neurogenesis. | Sandoval-Hernandez et al., 2015 |<sup>356</sup> |
| APP/PS1 mice p.o. 9 days. CFT. Hippocampal and cortical ABCA1, ABCG1, apoE, inflammatory markers, and Aβ. | CFT performance restored to level of WT control. ABCA1/ G1 and apoE increased. Non-significant reductions in Aβ. Iba1 significantly reduced; TNFs and others non-significant. | Skerrett et al., 2015 |<sup>357</sup> |

(continued on next page)
truncated ligand-binding domains (LBD) of LXR does not reflect the influence of a ligand on transcriptional output, which includes expression of ABCA1 and hundreds of other genes. Specifically, ABCA1 and SREBP1c expression require distinct combinations of nuclear coregulator displacement/replacement. LXR target genes are not controlled identically via the stabilization/derepression mechanism. ABCA1 is controlled via derepression, in which LXR “+” mice exhibit higher gene expression than LXR “−/−” mice at baseline, whereas SREBP1 (gene encoding SREBP1c) is controlled by the classical nuclear receptor model of receptor recruitment to the DNA promoter upon ligand binding, with basal expression in LXR “+/−” ≥ LXR “−/−”. Thus, unique ligands that are equipotent for LXRα and LXRβ LBD-binding in vitro can elicit unique transcriptional and phenotypic responses in complex biological systems.

A recent seminal paper describes the challenge for LXR ligand design: specifically, this work was focused on nonlipogenic ABCA1 inducers using in vivo phenotypic outputs of intestinal ABCA1 versus plasma triglycerides as binary ligand descriptors for multivariate statistical correlation with: i) H/D-exchange mass spectrometry; surface plasmon resonance binding to coregulators; LXR-LBD affinity; LXR transactivation; and ii) computational modeling. One clear observation from hydrogen-deuterium exchange and surface plasmon resonance data is that the almost identical ligand binding pockets of LXRα and LXRβ are not an insurmountable barrier to design of LXR ligands with selective pharmacology: different chemical structures stabilized overlapping but nonidentical regions of LXR. More lipogenic ligands stabilized helix-12 (H12) and coactivator peptide binding (Fig. 4); whereas stabilization of the H3/H5 interface and corepressor peptide binding may bias towards ABCA1 inducers. As a corollary to this work, simply optimizing ligand affinity for LXRβ-LBD versus LXRα-LBD will result in LXRβ selectivity, but not necessarily nonlipogenic ABCA1 inducers. Structures for a variety of LXR complexes are shown (including one in a heterodimeric complex with RXR bound to DNA) and compared with ER complexes showing similarity between NHR architecture, ligand binding, and coregulator recruitment.

A final complexity in designing LXR ligands is the extensive cross-talk that occurs among NHRs, such that activation of one may amplify or depress the expression and/or functional output of another. In addition to cross-talk, cross-reactivity between LXR and other NHRs is not uncommon. T0 is used as a benchmark LXR agonist; however, it has off-target activity at FXR. The LXR agonist GSK2033 binds to PPARs”. Fibrates, used successfully to treat hypertriglyceridemia, bind both PPARα and LXRs, with inhibition of lipogenesis and SREBP1c expression attributed to “antagonist” action at LXR. GSK2033, described as the first potent LXR agonist (IC50 = 31.8 nmol/L for LXRβ), also engages glucocorticoid receptor, pregnant X receptor, and FXR.

4.8. Phenotypic drug discovery strategies

Phenotypic drug discovery for nonlipogenic ABCA1 inducers is likely to identify some LXR ligands that act as SLMs and others that regulate NHRs, either by direct binding or by feedback modulation. Given the poor correlation of phenotype with binding affinity (for LXRα versus LXRβ) and the complexity of NHR feedback, phenotypic screening is the logical approach to discover nonlipogenic ABCA1 inducers. A target-agnostic approach that prioritizes phenotype allows for identification of compounds that engage novel targets or, potentially, multiple targets to produce the desired effect. Notably, both PPAR agonist E3317 and the HDACi phenotypic approaches.

A number of phenotypic screening efforts have been reported focusing on APOE transcription or secretion as the primary readout, some with ABCA1 upregulation as a secondary readout. However, in one case, the counterscreen was designed to remove ABCA1 inducers. The perceived lipogenic risk associated with LXR agonists led Pifer, Astra Zeneca, and others to screen CCF-STTG1 astrocytoma cells to identify hits that increase APOE, counterscreening to triage LXR ligands, although subsequent validation of resulting compounds in animal models is lacking. We recently described a luciferase-based phenotypic strategy employing an ABCA1 promoter to identify ABCA1 boosting compounds and a SREBF1 promoter to counter-screen against lipogenesis in HepG2 cells. This approach yielded multiple compounds with ABCA1-boosting, non-lipogenic profiles both in vitro and in vivo. Chemical optimization resulted in a lead compound that had beneficial effects in an obesogenic mouse model of T2D. The broad metabolic effects observed prompted further investigation, revealing a binding profile of full agonist activity at LXRα and partial agonist activity at LXRs, with weak antagonism of PPAR and RXR isomers. This strategy did not preclude LXR ligands from being identified; indeed, based on the promoter sequence, it was biased towards LXR ligands. Furthermore, this ABCA1-inducing LXR agonist was not only nonlipogenic, but also reduced triglycerides in the obesogenic mouse model.

| Compd. Animal system | Key finding | Ref. |
|----------------------|-------------|-----|
| 3Tg mice p.o. 6 days, MWM, hippocampal Aβ, gene methylation, and synaptic proteins (JMN). Hippocampal GFAP/IIIb1a1, LRP1, and lectin staining (Neuro Lett). | MWM retention restored to WT baseline; learning unaffected. No change in Aβ, PSD95 and synapsin-1 increased; and DNA methylation of synaptic genes decreased. Reduced GFAP and altered morphology, no change in microglia; increased LRP1; decreased vascular tortuosity with reduced perivascular Aβ. | Sandoval-Hernandez et al., 2016 (split across two articles) |
5. Conclusions

AD and related metabolic conditions are among the top causes of morbidity and mortality in the United States and worldwide, with existing therapies demonstrating minimal efficacy at reversing the progression of or enhancing survival from AD. Cholesterol metabolism and transport in both the CNS and periphery are central to the pathophysiology of AD and related diseases such as T2D and CVD, impacting such processes as Ab and NFT production and deposition, atherosclerosis, inflammatory signaling, and insulin resistance. Because of this critical importance of cholesterol homeostasis in these conditions, boosting expression or function of the primary cholesterol transport protein ABCA1 has been proposed as a therapeutic target. Drug development efforts to enhance ABCA1 have focused on nuclear hormone receptor—particularly, liver X receptor—agonists. These agonists have demonstrated promising results in preclinical AD models; however, their development and translation to the clinic has been hampered by an inability to avoid undesirable effects on triglyceride biogenesis. Recent research in LXR biology, as well as experience from drug discovery at other NHRs, suggests that the central paradigms that have driven LXR/ABCA1-based drug...
development are overly simplistic. In particular, the focus on developing agonists selective for LXR\(\alpha\) vs. LXR\(\beta\) isomers will not yield non-lipogenic ABCA1 inducers as was previously thought. Rather, future medicinal chemistry efforts should strive to produce selective receptor modulators (e.g., SLIMs or SPPARMs described above) that elicit only a small fraction of biological effects regardless of activity in receptor binding assays. Phenotypic, instead of target-based, drug discovery approaches are well-suited to approach this challenge; indeed, several in vitro and early preclinical screens using various phenotypic assays have yielded numerous promising development candidates.

Acknowledgments

Cutler T. Lewandowski was supported by NIH T32AG57468 (USA) and American Heart Association 20PRE35150022 (USA) and is a trainee in the University of Illinois Medical Scientist Training Program (USA). Additional funding was provided through the UCentre for Drug Discovery as supported by the National Center for Advancing Translational Sciences, NIH UL1TR002003 (USA).

Author contributions

Cutler T. Lewandowski wrote the original draft, produced figures and tables, and contributed to revisions. Megan S. Laham produced tables and figures and contributed to revisions. Gregory R.J. Thatcher provided supervision, acquired research funding, and contributed to revisions. Gregory R. J. Thatcher provided supervision, acquired research funding, and contributed to revisions.

Conflicts of interest

Gregory R. J. Thatcher is an inventor on patents owned by the University of Illinois. The other authors have no competing interests or relationships to disclose.

References

1. Alzheimer’s A. 2020 Alzheimer’s disease facts and figures. Alzheimer’s Dement 2020;16:391–460.
2. Alzheimer’s A. 2016 Alzheimer’s disease facts and figures. Alzheimer’s Dement 2016;12:459–509.
3. Briggs R, Kennelly SP, O’Neill D. Drug treatments in Alzheimer’s disease. Clin Med (Lond) 2016;16:247–53.
4. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord 2013;6:19–33.
5. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimer’s Res Ther 2014;6:37.
6. Berk C, Sabbagh MN. Successes and failures for drugs in late-stage development for Alzheimer’s disease. Drugs Aging 2013;30:783–92.
7. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y) 2020;6:e21050.
8. Wang HF, Shen XN, Li JQ, Suckling J, Tan CC, Wang YJ, et al. Clinical and biomarker trajectories in sporadic Alzheimer’s disease: a longitudinal study. Alzheimers Dement (Amst) 2020;12:e21095.
9. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396:413–46.
10. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006;66:1837–44.
11. Negash S, Wilson RS, Leurgans SE, Wolk DA, Schneider JA, Buchman AS, et al. Resilient brain aging: characterization of discordance between Alzheimer’s disease pathology and cognition. Curr Alzheimer Res 2013;10:844–51.
12. Yu L, Tatsaki S, Schneider JA, Arfanakis K, Duong DM, Wingo AP, et al. Cortical proteins associated with cognitive resilience in community-dwelling older persons. Jama Psychiatry 2020;77:1172–80.
13. Yu L, Petyuk VA, Gaiteri C, Mostafavi S, Young-Pearse T, Shah RC, et al. Targeted brain proteomics uncover multiple pathways to Alzheimer’s dementia. Ann Neurol 2018;84:78–88.
14. Graham EK, James BD, Jackson KL, Wilfroth EC, Boyle P, Wilson R, et al. Associations between personality traits and cognitive resilience in older adults. J Gerontol B Psychol Sci Soc Sci 2021;76:1–19.
15. Legueur N, Badissi M, Carter SF, de Crom S, van de Kreeke A, Vreeswijk R, et al. Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatr 2018;18:289.
16. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet 2019;51:404–13.
17. Dumitrascu L, Mahoney ER, Mukherjee S, Lee ML, Bush WS, Engelman CD, et al. Genetic variants and functional pathways associated with resilience to Alzheimer’s disease. Brain 2020;143:2561–75.
18. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujiimi K, Matsu Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 2010;75:764–70.
19. Boles M, Perea JR, Avila J. Alzheimer’s disease as an inflammatory disease. Biomol Concepts 2017;8:37–43.
20. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015;14:388–405.
21. Vieira MNN, Lima-Filho RAS, De Felice FG. Connecting Alzheimer’s disease to diabetes: underlying mechanisms and potential therapeutic targets. Neuropharmacology 2018;136:160–71.
22. Vagelatos NT, Estick GD. Type 2 diabetes as a risk factor for Alzheimer’s disease: the confounders, interactions, and neuropathology associated with this relationship. Epilepsia Rev 2013;35:152–60.
23. Li J, Cesari M, Liu F, Dong BR, Vellas B. Effects of diabetes mellitus on cognitive decline in patients with Alzheimer disease: a systematic review. Can J Diabetes 2017;41:114–9.
24. Chatterjee S, Peters SA, Woodward M, Meja Arango S,atty GD, Beckett N, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care 2016;39:300–7.
25. Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis. Alzheimers Dement (Amst) 2017;7:69–87.
26. Sabia S, Fayosse A, Dumurgier J, Schnitzler A, Empara JP, Ebmeier KP, et al. Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. BMJ 2019;366:l4414.
27. Jayaraman A, Pike CJ. Alzheimer’s disease and type 2 diabetes: multiple mechanisms contribute to interactions. Curr Diab Rep 2014;14:476.
28. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the cardiovascular health study cohort. Neurology 2010;75:460.
29. Peila R, Rodriguez BL, Launer LJ, Honolu-Asia Aging S. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study. Diabetes 2002;51:1256–62.
30. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002;59:1737–46.
ABCA1 and Alzheimer’s disease drug discovery

31. Gardner RC, Valcour V, Yaffe K. Dementia in the oldest old: a multifactorial and growing public health issue. *Alzheimer’s Res Ther* 2013; 5:27.

32. Kritsilis M, Koutsoudaki PN, Evangelou K, Gorgoulis VG, Papadopoulos D. Ageing, cellular senescence and neurodegenerative disease. *Int J Mol Sci* 2018; 19:2937.

33. Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, et al. Oxidative stress, aging, and diseases. *Clin Interv Aging* 2018; 13:757–72.

34. Bishop NA, Lu T, Yankner BA. Neural mechanisms of ageing and cognitive decline. *Nature* 2010; 464:529–35.

35. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. *J Geriatr Psychiatry Neurol* 2010; 23:213–27.

36. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. *J Neurosci* 2006; 26:10129–40.

37. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. *Nature* 1995; 373:523–7.

38. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin1. *Nature* 1996; 383:710–3.

39. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. *Nat Med* 1998; 4:97–100.

40. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. *Science* 1996; 274:99–102.

41. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. *EMBO Rep* 2006; 7:940–6.

42. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tanusso G, et al. High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptic toxicity without plaque formation. *J Neurosci* 2000; 20:4050–6.

43. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. *Biomed Eng* 2001; 17:517–65.

44. Lewandowski CT, Maldonado WJ, J LaDu MJ. Alzheimer’s disease pathology in APOE transgenic mouse models: the who, what, when, where, why, and how. *Neurobiol Dis* 2020; 139:104811.

45. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. *Neuron* 2003; 39:409–21.

46. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. *Neurobiol Aging* 2003; 24:1063–70.

47. Jackson RJ, Rudinskiy N, Herrmann AG, Croft S, Kim JM, Petrova V, et al. Human tau increases amyloid beta plaque size but not amyloid beta-mediated synapse loss in a novel mouse model of Alzheimer’s disease. *Eur J Neurosci* 2016; 44:3056–66.

48. Jankowsky JL, Zheng H. Practical considerations for choosing a mouse model of Alzheimer’s disease. *Mol Neurodegener* 2017; 12:89.

49. Lippl SLP, Smith ML, Flinn JM. A novel hAPP/tau mouse model of Alzheimer’s disease: inclusion of APP with tau exacerbates behavioral deficits and zinc administration heightens tangle pathology. *Front Aging Neurosci* 2018; 10:382.

50. Saito T, Mihiira N, Matsuba Y, Sasaguri H, Hashimoto S, Narasimhan S, et al. Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. *J Biol Chem* 2019; 294:12754–65.
apolipoprotein E isoforms determined by the amino-terminal domain. *Biochemistry* 2000;39:11657–66.
72. de Chaves EP, Narayanaswami V. Apolipoprotein E and cholesterol in aging and disease in the brain. *Future Lipidol* 2008;3:505–30.
73. Tamboli IY, Heo D, Rebeck GW. Extracellular proteolysis of apolipoprotein E (apoE) by secreted serine neuronal protease. *PLoS One* 2014;9:e93120.
74. Rohn TF. Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer’s disease. *Int J Mol Sci* 2013;14:14908–22.
75. Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, Marino C, Chimieiewska N, et al. Resistance to autonomic dominant Alzheimer’s disease in an APOE3 Chirstchurch homoygote: a case report. *Nat Med* 2019;25:1680–3.
76. Wardell MR, Brennan SO, Janus ED, Fraser R, Carrell RW. Apolipoprotein E2-Chirstchurch (136 Arg → Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. *J Clin Invest* 1987;80:483–90.
77. Altmann A, Tian L, Henderson VW, Greicius MD, Alzheimer’s Disease Neuroimaging Initiative. I. Sex modifies the APOE-related risk of developing Alzheimer disease. *Ann Neurol* 2014;75:563–73.
78. Neu SC, Pa J, Kukull W, Beekly D, Kuzma A, Gangadharan P, et al. Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. *JAMA Neurol* 2017;74:1178–89.
79. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breter IM. Diabetes mellitus and the risk of dementia: the Rotterdam study. *Neurology* 1999;53:1937–42.
80. Bellou V, Bellasis L, Tzoulaki I, Middleton LT, Ioannidis JPA, Evangelou E. Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses. *Alzheimers Dement* 2017;13:406–18.
81. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. *Proc Natl Acad Sci U S A* 2003;100:4162–7.
82. Kellar D, Craft S. Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. *Lancet Neurol* 2020;19:758–66.
83. Cai Z, Liu N, Wang C, Qin B, Zhou Y, Xiao M, et al. Role of RAGE in Alzheimer’s disease. *Cell Mol Neurobiol* 2016;36:483–95.
84. Hughes TM, Craft S. The role of insulin, amyloid beta-protein, and the beta-amyloid precursor protein in age-related dementia. *PLoS One* 2014;9:e93120.
85. Xu M, Zhao J, Zhang Y, Ma X, Dai Q, Zhi H, et al. Apolipoprotein E gene variants and risk of coronary heart disease: a meta-analysis. *BioMed Res Int* 2016;2016:3912175.
86. El-Lebedy D, Raslan HM, Mohammed AM. Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease. *Cardiovasc Diabetol* 2016;15:12.
87. Kunkle BW, Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. *Proc Natl Acad Sci U S A* 2003;100:4162–7.
88. Wingo AP, Fan W, Duong DM, Gerasimov ES, Dammer EB, Liu Y, et al. Shared proteome effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain. *Nat Neurosci* 2020;23:696–700.
89. Zetterberg H, Mortberg E, Song L, Chang L, Provudden GK, Patel PP, et al. Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid beta levels in humans. *PLoS One* 2011;6:e28263.
90. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, et al. Circle of Willis atherosclerosis: association with Alzheimer’s disease, neuritic plaques and neurofibrillary tangles. *Acta Neuropathol* 2007;113:31–21.
91. Bown CW, Liu D, Osborn KE, Gupta DK, Mendes LA, Pechman KR, et al. Apolipoprotein E genotype modifies the association between cardiac output and cognition in older adults. *J Am Heart Assoc* 2019;8:e011146.
92. Mayeux R, Ottman R, Maestre G, Ngai C, Tang MX, Ginsberg H, et al. Synergistic effects of traumatic head injury and apolipoprotein-epilson 4 in patients with Alzheimer’s disease. *Neurology* 1995;45:555–7.
148. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE promotes the proteolytic degradation of Aβ. Neuron 2008;58:681–93.

149. Cutler RG, Kelly J, Storie K, Pedersen WA, Tamamara A, Hatapa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci U S A 2004;101:2070–5.

150. Bogdanovic N, Bretillon L, Lund EG, Diczfalussy U, Lannfelt L, Winblad B, et al. On the turnover of brain cholesterol in patients with Alzheimer’s disease. Abnormal induction of the cholesterol-catabolic enzyme CYPI6 in glial cells. Neurosci Lett 2001;314:45–8.

151. Bretillon L, Siden A, Wahlund LO, Lutjohann D, Minthon L, Crispy M, et al. Plasma levels of 24S-hydroxycholesterol in patients with neurodegenerative diseases. Neurosci Lett 2000;293:87–90.

152. Yassine HN, Feng Q, Chiang J, Petrosspour LM, Fonteh AN, Chui HC, et al. ABCA1-mediated cholesterol efflux capacity to cerebrospinal fluid is reduced in patients with mild cognitive impairment and Alzheimer’s disease. J Am Heart Assoc 2016;5:e002886.

153. Teresa JC, Fernado C, Nancy MR, Gilberto VA, Alberto CR, Roberto RR. Association of genetic variants of ABCA1 with susceptibility to dementia: (SADEM study). Metab Brain Dis 2020;35: 915–22.

154. Wollmer MA, Streffer JR, Lutjohann D, Tsolaki M, Iakovidou V, Hegi T, et al. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer’s disease. Neurobiol Aging 2003;24:421–6.

155. Sundar PD, Feingold E, Minster RL, DeKosky ST, Kamboh MI. Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer’s disease. Neurobiol Aging 2007;28:856–62.

156. Nordestgaard LT, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt JG, Hoogeveen RM, Ali L, Prange KHM, Waissi F, van Sundar PD, Feingold E, Minster RL, DeKosky ST, Kamboh MI. ATP-binding cassette transporter A1: from metabolism to neurodegeneration. Neurobiol Dis 2014;72 P1 A:13–21.

157. Tang Q, Wang F, Yang J, Peng H, Li Y, Li B, et al. Revealing a novel landscape of the association between blood lipid levels and Alzheimer’s disease—a meta-analysis of a case-control study. Front Aging Neurosci 2019;11:570.

158. Feingold KD. Introduction to lipids and lipoproteins. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. EndoTest. South Dartmouth: MITTest.com, Inc.; 2000.

159. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009;29:431–8.

160. Schnitzer JG, Hoogeveen RM, Ali L, Prange KHM, Waissi F, van Weeghel M, et al. Atherogenic lipoprotein(a) increases vascular glycosylation, thereby facilitating inflammation and leukocyte extravasation. Circ Res 2020;126:1346–59.

161. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. J Lipid Res 2009;50 Suppl: S195–200.

162. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathy YV, Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 1992;33:141–66.

163. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol 2015;15:104–16.

164. Gall J, Frisidal E, Bittar R, Le Goff W, Bruckert E, Lensk P, et al. Association of cholesterol efflux capacity with clinical features of metabolic syndrome: relevance to atherosclerosis. J Am Heart Assoc 2016;5:e004808.

165. Zhu Y, Liao H, Xie X, Yuan Y, Lee TS, Wang N, et al. Oxidized LDL downregulates ATP-binding cassette transporter-1 in human vascular endothelial cells via inhibiting liver X receptor (LXR). Cardiovasc Res 2005;68:425–32.

166. Shao B, Tang C, Sinha A, Mayer PS, Davenport GD, Brot N, et al. Humans with atherosclerosis have impaired ABCA1, cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res 2014;114:1733–42.

167. Schaefer EJ, Santos RD, Asztalos BF. Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol 2010;21: 289–97.

168. Villarreal-Molina MT, Flores-Dorantes MT, Arellano-Canpos O, Villalobos-Compan M, Rodriguez-Cruz M, Miliar-Garcia A, et al. Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population. Diabetes 2008;57:509–13.

169. Doosti M, Najafi M, Reza JZ, Nikzamir A. The role of ATP-binding-cassette-transporter-A1 (ABCA1) gene polymorphism on coronary artery disease risk. Transl Res 2010;155:185–90.

170. Tang D, Cao S, Liu M, Park S. A meta-analysis of the associations between the ATP-binding cassette transporter ABCA1 R219K (rs2230806) polymorphism and the risk of type 2 diabetes in Asians. Horm Metab Res 2018;50:308–16.

171. Tai LM, Thomas R, Marottoli FM, Koster KP, Kanekiyo T, Morris AW, et al. The role of APOE in cerebrovascular dysfunction. Acta Neuropathol 2016;131:709–23.

172. Bowman GL, Kaye JA, Quinn JF. Dyslipidemia and blood–brain barrier integrity in Alzheimer’s disease. Curr Genet Geriatr Res 2012;2012:184042.

173. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes?. J Alzheimers Dis 2005;7:33–40.

174. Tabet K, Wang HY, Zhao K, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance. JRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122:1316–38.

175. van der Heide LP, Kamal A, Artola A, Gispel WH, Ramakers GM. Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-D-aspartate receptor and phosphatidylinositol-3-kinase-dependent manner. J Neurochem 2005;94:1158–66.

176. Mielke JG, Wang YT. Insulin, synaptic function, and opportunities for neuroprotection. Prog Mol Biol Transl Sci 2011;98:133–86.

177. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, et al. Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 2009;106:1971–6.

178. Campbell JM, Stephenson MD, de Courten B, Chapman I, Bellman SM, Aromataris E. Metformin use associated with reduced mild cognitive impairment in a community-dwelling people with diabetes: a national case-control study. J Clin Endocrinol Metab 2020;105:e963–72.
206. Barroeta-Espar I, Weinstock LD, Perez-Nievas BG, Meltzer AC, Siao
Guillemot-Legris O, Masquelier J, Everard A, Cani PD,
204. Huang NQ, Jin H, Zhou SY , Shi JS, Jin F. TLR4 is a link between
202. Yang Y , Song W. Molecular links between Alzheimer's disease and
deit threshold and cerebral cortex in Alzheimer disease. J 
197. Tang C, Liu Y, Yang W, Storey C, McMillen TS, Houston BA, et al.
199. Patel DC, Albrecht C, Pavitt D, Paul V , Pourreyron C, Newman SP, 
198. Vincent V , Thakkar H, Aggarwal S, Mridha AR, Ramakrishnan L, 
189. Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, 
ABCA1 and Alzheimer's disease drug discovery 1013
Learn Mem
mice.
J Neuroinflammation
Alhouayek M, Muccioli GG. High-fat diet feeding differentially af-
ASN Neuro
beta interact to induce cognitive and cerebrovascular dysfunction. 
Tai LM. Peripheral inflammation, apolipoprotein E4, and amyloid-
diabetes and Alzheimer's disease. 
Neuroscience
Salazar AM, Lamb BT. Inflammation as a central mechanism in 
tolerance, and insulin sensitivity. 
Hematopoietic ABCA1 deletion promotes monocytosis and worsens 
patients with ABCA1 mutations. J Atheroscler Thromb 2009;16:
296–2.

187. Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradhanan G, 
et al. Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. J Alzheimer's Dis 2016;51:501–14.
188. Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, 
Xie L, et al. Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study. Alzheimer Dis Assoc Disc 2017;31:107–13.
189. Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, 
Morgan A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease. J Alzheimer's Dis 2015;44:897–906.
190. Gold M, Aldertson C, Zvartav-Hind M, Egginton S, Saunders AM, 
Irizarry M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, pla-
201. Yang Y , Song W. Molecular links between Alzheimer's disease and
202. Yang Y , Song W. Molecular links between Alzheimer's disease and
Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Anantharamaiah GM. Synthetic peptide analogs of apolipoproteins. J Biol Chem 2009;284:32336–43.

Luciani MF, Denizot F, Savary S, Mattei MG, Chimini G. Cloning of two novel ABC transporters mapping on human chromosome 9. Genomics 1994;21:150–9.

Datta G, Chaddha M, Garber DW, Chung BH, Tytler EM, Dashti N. Biopeptides as potential therapeutics for Alzheimer’s disease. J Biol Chem 1985;260:10248–55.

Navab M, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphiphatic helical peptide. J Lipid Res 2001;42:1096–104.

Navab M, Anantharamaiah GM, Hama S, Hough G, Grijalva VR, et al. Oral D4F causes formation of pre-beta high density lipoprotein and improves high density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004;109:3215–20.

Chernick D, Zhong R, Li L. The role of HDL and HDL mimetic peptides as potential therapeutics for Alzheimer’s disease. Bio-molecules 2020;10:1276.

Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, et al. Oral administration of an Apo A-I mimetic peptide synthesized from n-amin o acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002;105:290–2.

Chernick D, Ortiz-Valle S, Jeong A, Swaminathan SK, Kandimalla KK, Rebeck GW, et al. High-density lipoprotein mimetic peptide 4F mitigates amyloid-beta-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia. J Neurochem 2018;147:647–62.

Handattu SP, Garber DW, Monroe CE, van Groen T, Kadish I, Nayar G, et al. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer’s disease. Neurobiol Dis 2009;34:525–34.

Buga GM, Frank JS, Mottino GA, Haddad MA, Hakkamian A, Tillisch JH, et al. D4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. J Lipid Res 2006;47:2146–60.

Laskowitz DT, McKenna SE, Song P, Wang H, Durham L, Yeung N, et al. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurotrauma 2007;24:1093–107.

Laskowitz DT, Thekdi AD, Thekdi SD, Han SK, Myers JK, Pizzo SV, et al. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol 2001;167:74–85.

Datta G, Chaddha M, Garber DW, Chung BH, Tytler EM, Dashni N, et al. The receptor binding domain of apolipoprotein E, linked to a model class A amphiphatic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 2000;39:213–20.
ABCA1 and Alzheimer’s disease drug discovery

LXR–ABCA1/ABCG1 cascade in adipocytes. Biochim Biophys Res Comm 2015; 468:900–5.

263. Wu YR, Shi XY, Ma CV, Zhang Y, Xu RX, Li J. Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway. Cardiovasc Diabetol 2019;18:146.

264. Yao Y, Li Q, Wang W, Zhang J, Gao P, Xu Y. Glucagon-like peptide-1 modulates cholesterol homeostasis by suppressing the mTOR-induced downregulation of ABCA1. Cell Physiol Biochem 2018; 50:679–93.

265. Lyu J, Imachi H, Fukunaga K, Sato S, Kobayashi T, Dong T, et al. Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. Mol Metab 2020;34:16–26.

266. Fennemilla GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study). Trials 2019;20:191.

267. Chai JT, Digby JE, Choudhary RP. GPR109A and vascular inflammation. Curr Atheroscler Rep 2013;15:325.

268. Offermanns S, Colletti SL, Lovenberg TW, Semple G, Wise A, AP II. International Union of Basic and Clinical Pharmacology. LXXIII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B). Pharmacol Rev 2011;63:269–90.

269. Gaidarov I, Chen X, Anthony T, Maciejewski-Lenoir D, Liaw C, Unett DJ. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential. Cell Signal 2013;25:2003–16.

270. Zhang LH, Kamanna VS, Ganji SH, Xiong XM, Kashyap ML. Petrov AM, Pikuleva IA. Cholesterol 24-hydroxylation by ABCA1 and Alzheimer’s disease drug discovery 1015

271. Xu GB, Yang LQ, Guan PP, Wang ZY, Wang P. Prostaglandin A1 receptor agonist activity in vivo. J Biol Chem 2014;289:14284–92.

272. Petrov AM, Pikuleva IA. Cholesterol 24-hydroxylation by CYP4A1: benefits of modulation for brain diseases. Neurotherapeutics 2019;16:635–48.

273. van der Kant R, Langness VF, Herrera CM, Williams DA, Fong LK, Leestemaker Y, et al. Cholesterol metabolism Is a druggable axis that independently regulates tau and amyloid-beta in iPSC-derived Alzheimer’s disease neurons. Cell Stem Cell 2019;24:363–375.e9.

274. Mast N, Norcross R, Anderson U, Shou M, Nakayama K, Bjorkhem I, et al. Broad substrate specificity of human cytochrome P450 4A6A1 which initiates cholesterol degradation in the brain. Biochemistry 2003;42:14284–92.

275. Mast N, Charvet C, Pikuleva IA, Stout CD. Structural basis of drug binding to CYP4A61, an enzyme that controls cholesterol turnover in the brain. J Biol Chem 2010;285:31783–95.

276. Mast N, Verwilst P, Wilkey CJ, Guengerich FP, Pikuleva IA. In vitro activation of cytochrome P450 4A6A1 (CYP46A1) by efavirenz-related compounds. J Med Chem 2020;63:6477–88.

277. Xu Y, Xu Y, Bao Y, Hong B, Si S. Identification of dehydroxy-trichostatin A as a novel up-regulator of the ATP-binding cassette transporter A1 (ABCA1). Molecules 2011;16:7183–98.

278. Gao Q, Wei A, Chen F, Chen X, Ding W, Ding Z, et al. Enhancing PPARgamma by HDAC inhibition reduces foam cell formation and atherosclerosis in ApoE deficient mice. Pharmacol Res 2020;160:105059.

279. Van den Bossche J, Neele AE, Hoeksema MA, de Heij F, Boshuizen MC, van der Velden S, et al. Inhibiting epigenetic enzymes to improve athrogenic macrophage functions. Biochem Biophys Res Comm 2014;455:396–402.

280. Dresselhaus E, Duerr JM, Vincent F, Sylvain EK, Beyna M, Lanyon LF, et al. Class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion. PLoS One 2018;13:e0194661.

281. Weikum ER, Liu X, Ortland EA. The nuclear receptor superfamily: a structural perspective. Protein Sci 2018;27:1876–92.

282. Li D, Li T, Wang F, Tian H, Samuels HH. Functional evidence for retinoid X receptor (RXR) as a nonsilent partner in the thyroid hormone receptor/RXR heterodimer. Mol Cell Biol 2002;22:5782–92.

283. Boergesen M, Pedersen TA, Gross B, van Heeringen SJ, Hagenbeek D, Bindesbøll C, et al. Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor alpha in mouse liver reveals extensive sharing of binding sites. Mol Cell Biol 2012;32:852–67.

284. Chawla A, Boisvert WA, Lee CH, Lafitte BA, Barak Y, Joseph SB, et al. A PPAR gamma–LXR–ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7:161–71.

285. Nishimaki-Mogami T, Tamehiro N, Sato Y, Okuhira K, Sai K, Kagechika H, et al. The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines. Biochem Pharmacol 2008;76:1006–13.

286. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997;386:407–10.

287. Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, et al. The RXR agonist bezarotene increases cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 2006;26:2731–7.

288. Lalloyer F, Pedersen TA, Gross B, Lestavel S, Yous S, Vallez E, et al. Retinoid xeroxarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. Arterioscler Thromb Vasc Biol 2009;29:1488–95.

289. Kramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012;335:1503–6.

290. Fitz NF, Cronican AA, Leftorov I, Koldamova R. Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 2013;340. 924-c.

291. Price AR, Xu G, Siemieniak ZB, Smithsonian LA, Borchelt DR, Golde TE, et al. Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 2013;340. 924-d.

292. Tesser I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, et al. Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 2013;340. 924-e.

293. Veeraraghavulu K, Zhang C, Miller S, Hefendehl JK, Papasakoulas TW, Ulrich J, et al. Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 2013;340. 924-f.

294. Tai LM, Koster KP, Luo J, Lee SH, Wang YT, Collins NC, et al. Amyloid-beta pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J Biol Chem 2014;289:30538–55.

295. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581–93.

296. Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease. Alzheimer’s Res Ther 2016;8:4.

297. Ren G, Bao W, Zeng Z, Zhang W, Shang C, Wang M, et al. Retinoid X receptor alpha nitro-ligand Z-10 and its optimized derivative Z-36 reduce beta-amyloid plaques in Alzheimer’s disease mouse model. Mol Pharm 2019;16:480–8.

298. Yuan C, Guo X, Zhou Q, Du F, Jiang W, Zhou X, et al. OAB-14, a bexarotene derivative, improves Alzheimer’s disease-related pathologies and cognitive impairments by increasing beta-amyloid clearance in an APOE/PS1 mouse. Biochim Biophys Acta Mol Basis Dis 2019;1865:161–80.
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Chandra S, Pahan K. Gemfibrozil, a lipid-lowering drug, lowers ferri N, Corsini A, Sirtori C, Ruscica M. PPAR-alpha agonists are Ayaori M, Yakushiji E, Ogura M, Nakaya K, Hisada T, Uto-Kondo H, Silva JC, de Oliveira EM, Turato WM, Trossini GHG, Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Acta Pharmacol Sin 2015;36:44–50.

Ayaori M, Yakushiji E, Ogura M, Nakaya K, Hisada T, Uto-Kondo H, Silva JC, de Oliveira EM, Turato WM, Trossini GHG, Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2011;2:236–40.

Chinioti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001;7:53–8.

Ogata M, Tsujita M, Hossain MA, Akita N, Gonzalez FJ, Staels B, et al. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis 2009;205:413–9.

Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410–8.

Ferri N, Corsini A, Sirtori C, Ruscica M. PPAR-alpha agonists are still on the rise: an update on clinical and experimental findings. Expert Opin Investig Drugs 2017;26:593–602.

Chanda S, Pahan K, Gemfibrozil, a lipid-lowering drug, lowers amyloid plaque pathology and enhances memory in a mouse model of Alzheimer’s disease via peroxisome proliferator-activated receptor alpha. J Alzheimers Dis Rep 2019;3:149–68.

Silva JC, de Oliveira EM, Turato WM, Trossini GHG, Maltrarollo VG, Pitta MGR, et al. QQ-11: a new PPAR agonist improves obesity-induced metabolic alterations in LDLR−/− mice. Int J Obes (Lond) 2018;42:1062–72.

Wang X, Luo J, Li N, Liu L, Han X, Liu C, et al. E3317 promotes cholesterol efflux in macrophage cells via enhancing ABCA1 expression. Biochem Biophys Res Commun 2018;504:68–74.

Oliver Jr WR, Shenk JL, Snaith MR, Russell CS, Plunet KD, Bodkin NL, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001;98:5306–11.

Chamberlain S, Gabriel H, Strittmatter W, Didsbury J. An exploratory Phase IIa study of the PPAR delta/gamma agonist T0901317 assessing metabolic and cognitive function in subjects with mild to moderate Alzheimer’s disease. J Alzheimers Dis 2020;73:1085–103.

Beyer TP, Schmidt RJ, Foxworthy P, Zhang Y, Dai J, Bensch WR, et al. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. J Pharmacol Exp Ther 2004;309:861–8.

Govindarajulu M, Pinky PD, Bloemer J, Ghanie N, Supprianamian V, Amin R. Signaling mechanisms of selective PPARgamma modulators in Alzheimer’s disease. PPAR Res 2018;2018:2010675.

Godoy JA, Zolezzi JM, Inesrosta NC. INT131 increases dendritic arborization and protects against Abeta toxicity by inducing mitochondrial changes in hippocampal neurons. Biochem Biophys Res Commun 2017;490:955–62.

Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism. J Endocrinol 2010;204:233–40.

Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov 2014;13:433–44.

Jakobsson T, Treuter E, Gustafsson JA, Steffen K. R. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci 2012;33:394–404.
Koura M, Yamaguchi Y, Kurobuchi S, Sumida H, Watanabe Y, Enomoto T, et al. Discovery of a 2-hydroxyacetophenone derivative as an outstanding linker to enhance potency and beta-selectivity of liver X receptor agonist. *Bioorg Med Chem* 2016;24:3436–46.

Zheng Y, Zhuang L, Fan KY, Tice CM, Zhao W, Lotosda SD, Dong C, et al. Discovery of a novel, orally efficacious liver X receptor (LXR) beta agonist. *J Med Chem* 2016;59:3264–71.

Tice CM, Noto PB, Fan KY, Zhao W, Lotosda SD, Dong C, et al. Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropropylro[3,4-e]pyrazole core. *Bioorg Med Chem Lett* 2016;26:5044–50.

Kirschgessner TG, Martin R, Sleph P, Grimm D, Liu X, Lupisella J, et al. Pharmacological characterization of a novel liver X receptor agonist with partial LXRalpha activity and a favorable window in nonhuman primates. *J Pharmacol Exp Ther* 2015;352:305–14.

Kock E, Martin R, Xie Y, Flatt B, Schweiger E, Wang TL, et al. Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRbeta. *Bioorg Med Chem Lett* 2015;25:372–7.

Kick EK, Busch BB, Martin R, Stevens WC, Bolli V, Xie Y, et al. Discovery of highly potent liver X receptor beta agonists. *ACS Med Chem Lett* 2016;7:1207–12.

Kirschgessner TG, Sleph P, Ostrowski J, Lupisella J, Ryan CS, Liu X, et al. Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neuphilts. *Cell Metab* 2016;24:223–33.

Katz A, Udata C, Ott E, Hickey L, Burczynski ME, Burghart P, et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. *J Clin Pharmacol* 2009;49:643–9.

Honzuini S, Shima A, Hiroshima A, Koiyayama T, Ushakata N, Terasaka N. LXRalpha regulates human CETP expression in vitro and in transgenic mice. *Atherosclerosis* 2010;212:139–45.

Hong C, Marshall SM, McDaniel AL, Graham M, Layne JD, Cai L, et al. The LXR–Idol axis differentially regulates plasma LDL levels in primates and mice. *Cell Metab* 2014;20:910–8.

Lefterov I, Bookout A, Wang Z, Staufenbiel M, Mangelsdorff D, Koldamova R. Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment. *Mol Neurodegener* 2007;2:20.

Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, et al. The LXR agonist T0901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer’s disease. *J Mol Neurosci* 2007;34:621–9.

Fitz NF, Cronican A, Pham T, Fogg A, Fauq AH, Chapman R, et al. Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. *J Neurosci* 2010;30:6862–72.

Terwel D, Steffensen KR, Verghese PB, Kammer MP, Gustafsson JA, Holtzman DM, et al. Critical role of astrogial apolipoprotein E and liver X receptor-alpha expression for microglial Abeta phagocytosis. *J Neurosci* 2011;31:7049–59.

Vannmiero T, Rutten K, Dederen J, Bloks VW, Van Vark-van der Zee LC, Kuipers F, et al. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. *Neurolbd Aging* 2011;3:1262–72.

Cui W, Sun Y, Wang Z, Xu C, Peng Y, Li R. Liver X receptor activation attenuates inflammatory response and protects cholercinic neurons in APPPS1 transgenic mice. *Neuroscience* 2012;210:200–10.

Fitz NF, Castronio EL, Carter AV, Kodali R, Lefterov I, Koldamova R. Improvement of memory deficits and amyloid-beta clearance in aged APP23 mice treated with a combination of anti-amyloid-beta antibody and LXR agonist. *J Alzheimer Dis* 2014;41:535–49.

Carter AV, Letronne F, Fitz NF, Mounier A, Wolfe CM, Nam KN, et al. Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice. *PLoS One* 2017;12:e0172161.

Wesson DW, Borkowski AH, Landreth GE, Nixon RA, Levy E, Wilson DA. Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer’s beta-amyloidosis mouse model. *J Neurosci* 2011;31:15962–71.

Stukas S, May S, Wilkinson A, Chan I, Donkin I, Wellington CL. The LXR agonist GW3965 increases apoA-I protein levels in the central nervous system independent of ABCA1. *Biochim Biophys Acta* 2012;1821:536–46.

Sandoval-Hernandez AG, Buitrago L, Moreno H, Cardona-Gomez GP, Arboleda G. Role of liver X receptor in AD pathology. *PLoS One* 2015;10:e0145467.

Skerritt R, Pellegrino MP, Casali BT, Taraboanta L, Landreth GE. Combined liver X receptor/peroxisome proliferator-activated receptor gamma agonist treatment reduces amyloid beta levels and improves behavior in amyloid precursor protein/presenilin 1 mice. *J Biol Chem* 2015;290:21591–602.

Sandoval-Hernandez AG, Hernandez HG, Restrepo A, Munoz JL, Bayon GF, Fernandez AF, et al. Liver X receptor agonist modifies the DNA ethylation profile of synapse and neuroregeneration-related genes in the triple transgenic mouse model of Alzheimer’s disease. *J Mol Neurosci* 2016;58:243–53.

Sandoval-Hernandez AG, Restrepo A, Cardona-Gomez GP, Arboleda G. LXR activation protects hippocampal microvasculature in very old triple transgenic mouse model of Alzheimer’s disease. *Neurosci Lett* 2016;621:15–21.

Smith CL, O’Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. *Endocr Rev* 2004;25:45–71.

Katzenellenbogen BS, Choi I, Delage-Mouroux R, Ediger TR, Martini PG, Montano M, et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. *J Steroid Biochem Mol Biol* 2000;74:279–85.

Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. *Eur J Cancer* 2008;44:30–8.

Leaney AE, Beck P, Biddle S, Brown P, Grace PB, Hudson SC, et al. Analysis of supplements available to UK consumers purporting to contain selective androgen receptor modulators. *Drug Test Anal* 2021;13:122–7.

Bunay J, Fouache A, Trousson A, de Joussineau C, Bouchareb E, Zhu Y, et al. Screening for liver X receptor modulators: where are we and for what use?. *Br J Pharmacol* 2021;178:3277–93.

Viennos E, Mouzat K, Dufour J, Morel L, Lobaccaro JM, Baron S. Selective liver X receptor modulators (SLiMs): what use in human health?. *Mol Cell Endocrinol* 2012;351:129–41.

Griffett K, Bursis TP. Promiscuous activity of the LXR antagonist GSK2930 in a mouse model of fatty liver disease. *Biochem Biophys Res Commun* 2016;479:424–8.

Griffett K, Solt LA, El-Gendy Bel D, Kamenecka TM, Bursis TP. A liver-selective LXR inverse agonist that suppresses hepatic steatosis. *ACS Chem Biol* 2013;8:559–65.

Gabbri C, Warner M, Gustafsson JA. Action mechanisms of liver X receptors. *Biochem Biophys Res Commun* 2014;446:647–50.

Li N, Wang X, Xu Y, Yin L, Zhu N, Liu P, et al. Identification of a novel liver X receptor agonist that regulates the expression of key cholesterol homeostasis genes with distinct pharmacological characteristics. *Mol Pharmacol* 2017;91:264–76.

Phelan CA, Weaver JM, Steger DJ, Joshi S, Maslany JT, Collins JL, et al. Selective partial agonism of liver X receptor alpha is related to differential coresspor recruitment. *Mol Endocrinol* 2008;22:2241–9.

Wagner BL, Vallezor AF, Shao G, Dauge CL, Bischoff ED, Petrowski M, et al. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. *J Cell Biol* 2003;163:5780–9.

Ramón-Vazquez A, de la Rosa JV, Tabraue C, Lopez F, Díaz-Chico BN, Bosca L, et al. Common and differential transcriptional actions of nuclear receptors liver X receptors alpha and beta in macrophages. *Mol Cell Biol* 2019;39.

Toroczkí D, Szanto A, Nagy L. Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages. *Mol Aspects Med* 2009;30:134–52.
Belorusova AY, Evertsson E, Hovdal D, Sandmark J, Britt E, Maxvall I, et al. Structural analysis identifies an escape route from the adverse lipogenic effects of liver X receptor ligands. *Commun Biol* 2019;2:431.

Chen Z, Chen H, Zhang Z, Ding P, Yan X, Li Y, et al. Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors. *Eur J Med Chem* 2020;206:112793.

Lou X, Toresson G, Benod C, Suh JH, Philips KJ, Webb P, et al. Structure of the retinoid X receptor alpha–liver X receptor beta (RXRalpha–LXRbeta) heterodimer on DNA. *Nat Struct Mol Biol* 2014;21:277–81.

de Vera IMS, Zheng J, Novick S, Shang J, Hughes TS, Brust R, et al. Synergistic regulation of coregulator/nuclear receptor interaction by ligand and DNA. *Structure* 2017;25:1506–18.

Xu P, Zhai Y, Wang J. The role of PPAR and its cross-talk with CAR and LXR in obesity and atherosclerosis. *Int J Mol Sci* 2018;19:1260.

Ide T, Shimano H, Yoshihara T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXR suppress lipid degradation gene promoters through inhibition of PPAR signaling. *Mol Endocrinol* 2003;17:1255–67.

Yoshihara T, Ide T, Shimano H, Yahagi N, Amemiya-Kudo M, Matsuzaka T, et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. *Mol Endocrinol* 2003;17:1240–54.

Xiao L, Xie X, Zhai Y. Functional cross-talk of CAR–LXR and ROR–LXR in drug metabolism and lipid metabolism. *Adv Drug Deliv Rev* 2010;62:1316–21.

Houck KA, Borchert KM, Hepler CD, Thomas JS, Bramlett KS, Michael LF, et al. T0901317 is a dual LXR/FXR agonist. *Mol Genet Metab* 2004;83:184–7.

Thomas J, Bramlett KS, Montrose C, Foxworthy P, Eacho PL, McCann D, et al. A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha) versus liver X receptor. *J Biol Chem* 2003;278:2403–10.

Fan J, Zareyan S, Zhao W, Shimizu Y, Pfeifer TA, Tak JH, et al. Identification of a chrysanthemic ester as an apolipoprotein E inducer in astrocytes. *PLoS One* 2016;11:e0162384.

Zhao W, Fan J, Kulic I, Koh C, Clark A, Meuller J, et al. Axl receptor tyrosine kinase is a regulator of apolipoprotein E. *Mol Brain* 2020;13:66.

Finan GM, Realubit R, Chung S, Lutjohann D, Wang N, Cirrito JR, et al. Bioactive compound screen for pharmacological enhancers of apolipoprotein E in primary human astrocytes. *Cell Chem Biol* 2016;23:1526–38.

Seneviratne U, Huang Z, Am Ende CW, Butler TW, Cleary L, Dresselhaus E, et al. Photoaffinity labeling and quantitative chemical proteomics identify LXRbeta as the functional target of enhancers of astrocytic apoE. *Cell Chem Biol* 2021;28:148–157.e7.

Tian LW, Feng Y, Shimizu Y, Pfeifer TA, Wellington C, Hooper JN, et al. ApoE secretion modulating bromotyrosine derivative from the Australian marine sponge *Callyspongia* sp. *Bioorg Med Chem Lett* 2014;24:3537–40.

Ben Aissa M, Lewandowski CT, Ratia KM, Lee SH, Layden BT, LaDu MJ, et al. Discovery of nonlipogenic ABCA1 inducing compounds with potential in Alzheimer’s disease and type 2 diabetes. *ACS Pharmacol Transl Sci* 2021;4:143–54.

Lewandowski CT, Khan MW, BenAissa M, Dubrovskyi O, Ackerman-Berrier M, LaDu MJ, et al. Metabolomic analysis of a selective ABCA1 inducer in obesogenic challenge provides a rationale for therapeutic development. *EBioMedicine* 2021;66:103287.